Connection

Denis Guttridge to Antineoplastic Agents

This is a "connection" page, showing publications Denis Guttridge has written about Antineoplastic Agents.
Connection Strength

0.350
  1. The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia. Cancer Res. 2018 12 01; 78(23):6680-6690.
    View in: PubMed
    Score: 0.093
  2. Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Mol Cancer Ther. 2017 02; 16(2):344-356.
    View in: PubMed
    Score: 0.082
  3. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther. 2016 05; 15(5):1018-28.
    View in: PubMed
    Score: 0.078
  4. Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. Pediatr Blood Cancer. 2009 Aug; 53(2):136-44.
    View in: PubMed
    Score: 0.050
  5. IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res. 2008 Oct 15; 68(20):8351-60.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.